DexDesign: an OSPREY-based algorithm for designing de novo D-peptide inhibitors.

Area of Science:

• Biochemistry
• Computational Biology
• Drug Discovery

Background:

• PDZ domains are critical in cellular processes, and their dysfunction is linked to diseases like cancer and cystic fibrosis.
• D-peptide inhibitors offer therapeutic advantages, including enhanced stability and reduced immunogenicity, making them promising drug candidates.

Purpose of the Study:

• To introduce DexDesign, a novel algorithm for de novo computational design of D-peptide inhibitors targeting PDZ domains.
• To demonstrate the application of DexDesign in generating potential therapeutic agents for CAL and MAST2 PDZ domains.

Main Methods:

• Development of DexDesign, an OSPREY-based algorithm incorporating Minimum Flexible Set, K*-based Mutational Scan, and Inverse Alanine Scan.
• Application of DexDesign to design D-peptide inhibitors for PDZ domain targets CAL and MAST2.
• Introduction of a novel framework for analyzing de novo peptide performance.

Main Results:

• DexDesign successfully generated novel D-peptide inhibitors for CAL and MAST2 PDZ domains.
• The designed D-peptides are predicted to exhibit stronger binding affinities to their targets than endogenous ligands.
• An implementation of DexDesign is provided within the OSPREY software.

Conclusions:

• DexDesign is a powerful tool for designing effective D-peptide inhibitors for PDZ domains.
• The generated D-peptides show significant therapeutic potential for treating PDZ-related diseases.
• The computational approach advances the field of protein design and therapeutic development.